Organon site directory

Organon
- Brazil
- Canada English French
- Latin America
- Mexico
- USA
Organon
- Austria
- Belgium Dutch English French
- Bulgaria
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg English French
- Netherlands Dutch English
- Norway
- Poland
- Portugal
- Romania
- Russia
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland French German English
- Ukraine Ukrainian
- United Kingdom
Organon
- Australia
- Hong Kong, China
- Indonesia
- Japan
- Malaysia
- New Zealand
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
Organon
- Egypt
- Israel
- Jordan
- KSA
- Kuwait
- Lebanon
- Northwest Africa French Arabic Turkey
- Oman
- South Africa
- Turkey
- UAE

View all locations and contact information

What can we help you find?

Search site

Search for:

Isabel Deslongchamps

Interim Executive Director, Biosimilars – Biologics

Biography to come

Connect with us on social

Opens a new window

Company

About us
Our mission, vision & values
Her Professional Journey
Our leaders

Resources

Our products
Media

Contact information

Contact us
Join our team

Cookie Policy
Privacy Notice
Terms of Use
Terms and Conditions for Sales
Community Engagement Guidelines
Statement of Organon on Forced Labour
Sitemap

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept